# Angio8

> Angio8 (Shenzhen Tonglu Technology, 通甪科技) is a medical robotics company building a surgical robot and treatment platform for minimally invasive vascular interventional procedures. Its system lets physicians remotely manipulate catheters and guidewires with force feedback, aiming to make interventional surgery safer, more precise, and less reliant on repeated radiation exposure for the operating team. Founded in 2021 and based in Shenzhen's Bao'an District, the company is led by co-founder and CEO Yunfei (Richard) Cao and is backed by investors including Oriental Fortune Capital, Kangyu Capital and Ruiqian Capital.

- **Founded:** 2021
- **Headquarters:** Shenzhen, Guangdong, China
- **Founders:** Yunfei (Richard) Cao (Co-Founder & CEO)
- **Team size:** ~4 employees (early-stage)
- **Products:** Vascular Interventional Surgical Robot, Interventional Treatment Platform
- **Notable:** Developed a vascular interventional surgical robot and treatment platform as an early entrant in China's endovascular robotics space, Closed a Series A round in 2023 led by established medtech investors, followed by a further round in 2025, Built a lean engineering team combining medical electronics, embedded systems and AI, working to IEC 62304 medical-software standards

## Products & services

- **Vascular Interventional Surgical Robot** — A robotic system that lets physicians remotely manipulate catheters and guidewires during minimally invasive vascular procedures, using force sensing to preserve tactile feedback and improve precision.
- **Interventional Treatment Platform** — An integrated hardware-and-software platform pairing the robot with the imaging and control environment of the catheterization lab, engineered to medical safety standards (IEC 62304).

## Achievements

- Developed a vascular interventional surgical robot and treatment platform as an early entrant in China's endovascular robotics space
- Closed a Series A round in 2023 led by established medtech investors, followed by a further round in 2025
- Built a lean engineering team combining medical electronics, embedded systems and AI, working to IEC 62304 medical-software standards

## Latest updates

- **2025-09** — Angio8 completed a follow-on funding round (reported as A+/later-stage), with capital directed toward technology R&D and product commercialization.
- **2023-05** — Angio8 closed a Series A round of tens of millions RMB from Oriental Fortune Capital, Kangyu Capital and Ruiqian Capital to accelerate R&D and move toward clinical trials.

## Links

- Website: https://angio8.com
- LinkedIn: http://www.linkedin.com/company/angio8global

---

Profile page: https://yespress.io/angio8
Published by YesPress — https://yespress.io
Last updated: 2026-07-22